16 noviembre 2017

Pharmamar . Pipeline Actualizado .

Tres Ensayos Clinicos con Aplidin para el Tratamiento de Multiple Myeloma :

*.- Doble Combinación .
*.- Triple Combinación .
*.- Cuadruple Combinación .

A destacar la Cuadruple Combinación iniciada el pasado 9 de Agosto :

PharmaMar starts a quadruple combination study with Aplidin for the treatment of multiple myeloma .

* Aplidin® is an ideal compound for combining with other therapies given its absence of Hematological toxicity, excellent safety profile along with its already demonstrated tolerance in triple combination .

* The success of this study will place Aplidin® at the front line of multiple myeloma treatment .

* The trial looks at combating multiple myeloma with the synergies of different mechanisms of action, increasing the possibility of success.